Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung

Journal of Nippon Medical School

Volumn 74, Issue 6, 2007, Pages 402-408

  Saitoh, Erika ^a,b   Yokomizo, Yuki ^a   Chang, Chin Hung ^c   Eremenco, Sonya ^d   Kaneko, Hiyori ^e,f   Kobayashi, Kunihiko ^a,e,f  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Research and Education   (United States)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f East Japan Chesters Group   (Japan)

Author keywords

Cross cultural comparison; Functional assessment of cancer therapy lung; Japanese; Lung cancer subscale; Lung carcinoma; Quality of life; Questionnaire

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER THERAPY; CONSTRUCT VALIDITY; CULTURAL FACTOR; FACTORIAL ANALYSIS; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; JAPAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE;

EID: 37349031765     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.74.402     Document Type: Article

References (12)

1. Kobayashi K, Takeda F, Teramukai S, et al.: A cross-Validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998; 34: 810-815.
2. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
3. Fumimoto H, Kobayashi K, Chang CH, et al: Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 2001; 10: 701-709.
4. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
5. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297.
6. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55: 285-295.
7. LoRusso PM, Herbst RS, Rischin D, et al: Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 2003; 9: 2040-2048.
8. Mark G, Ronald B, Roy S, et al: Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer A Randomized Trial. JAMA 2003; 290: 2149-2158.
9. Cella D, Herbst RS, Lynch TJ, et al: Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005; 23: 2946-2954.
10. Fukuoka M, Yano S, Giaccone G, et al: Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-2246.
11. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomised trial. JAMA 2003; 290: 2149-2158.
12. Cella D: Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol 2003; 30 (1 Suppl 1): 39-48.